摘要
沙利度胺又名酞胺哌啶酮或反应停,目前被广泛用于多发性骨髓瘤（MM）及其他血液病的治疗。资料显示沙利度胺有益于急性髓细胞白血病（AML）的治疗,但未见沙利度胺单药治疗诱导AML完全缓解（CR）的报道。现将我科1例以沙利度胺单药诱导CR急性单核细胞白血病报告如下,并进行相关文献复习。
There is no report about thalidomide-based monotherapy inducing acute monocytic leukemia complete remission.Now,we reported a case and reviewed the literature.This patient was diagnosed with AML-M5 b,high white cells and secondary aphthous.Because the patient refused chemotherapy,only thalidomide 50to100mg/d was used to treat after hdroxyurea was given to reduce the number of white cells.After about 2weeks the patient achieved complete remission.The mechanism of thalidomide treatment for AML is believed to be mainly inhibition of angiogenesis,immunomodulatory,inhibiting cytokines of microenvironment,direct inhibition of AML cell proliferation and inducing apoptosis.Presumably,the patient＇s leukemia cell differentiation is relatively strong adhesive and invasive,and their survival depend more on angiogenesis and interaction with the microenvironment,so thalidomide may target acute monocytic leukemia more specifically and effectively,which deserves further study.
出处
《临床血液学杂志》
CAS
2017年第1期66-68,共3页
Journal of Clinical Hematology
基金
深圳市科技创新项目(No:JCYI20140414123738256)
